DK3181691T3 - Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme - Google Patents

Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme Download PDF

Info

Publication number: DK3181691T3
Authority: DK; Denmark
Prior art keywords: same; pharmaceutical composition; composition including; fgf23 antibody; fgf23
Prior art date: 2007-02-14

Application number

DK17152168.5T

Other languages

English (en)

Inventor

Yuji Yamazaki

Itaru Urakawa

Hitoshi Yoshida

Yukiko Aono

Takeyoshi Yamashita

Takashi Shimada

Hisashi Hasegawa

Original Assignee

Kyowa Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-14

Filing date

2008-02-14

Publication date

2020-08-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3181691(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-14 Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd

2020-08-17 Application granted granted Critical

2020-08-17 Publication of DK3181691T3 publication Critical patent/DK3181691T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Dermatology (AREA)
Neurology (AREA)

DK17152168.5T 2007-02-14 2008-02-14 Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme DK3181691T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007034018		2007-02-14
EP12170984.4A EP2502996B1 (en)	2007-02-14	2008-02-14	Anti-FGF23 antibody and pharmaceutical composition comprising the same

Publications (1)

Publication Number	Publication Date
DK3181691T3 true DK3181691T3 (da)	2020-08-17

Family

ID=39690189

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK12170984.4T DK2502996T3 (da)	2007-02-14	2008-02-14	Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme
DK17152168.5T DK3181691T3 (da)	2007-02-14	2008-02-14	Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme
DK08711707.3T DK2128253T3 (da)	2007-02-14	2008-02-14	Anti-fgf23-antistof og farmaceutisk sammensætning omfattende samme

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK12170984.4T DK2502996T3 (da)	2007-02-14	2008-02-14	Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK08711707.3T DK2128253T3 (da)	2007-02-14	2008-02-14	Anti-fgf23-antistof og farmaceutisk sammensætning omfattende samme

Country Status (23)

Country	Link
US (4)	US7883705B2 (da)
EP (3)	EP2128253B1 (da)
JP (1)	JP4800396B2 (da)
KR (1)	KR101462291B1 (da)
CN (2)	CN102702355B (da)
AU (1)	AU2008215346B2 (da)
CA (1)	CA2677782C (da)
CY (3)	CY1118835T1 (da)
DK (3)	DK2502996T3 (da)
ES (3)	ES2811318T3 (da)
FR (1)	FR18C1032I2 (da)
HK (2)	HK1140228A1 (da)
HR (2)	HRP20170548T1 (da)
HU (3)	HUE050517T2 (da)
LT (3)	LT3181691T (da)
LU (2)	LUC00081I2 (da)
NL (1)	NL300945I2 (da)
NO (1)	NO2018025I1 (da)
PL (3)	PL2128253T3 (da)
PT (3)	PT2502996T (da)
SI (2)	SI2502996T1 (da)
TW (1)	TWI422593B (da)
WO (1)	WO2008099969A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2344679T3 (es) *	2000-08-11	2010-09-03	Kyowa Hakko Kirin Co., Ltd.	Polipeptidos que controlan el metabolismo del acido fosforico, el metabolismo del calcio, el metabolismo de la calcificacion y de la vitamina d y moleculas de adn que los codifican.
KR101016476B1 (ko) *	2001-12-28	2011-02-24	교와 핫꼬 기린 가부시키가이샤	섬유아세포 증식 인자-23에 대한 항체
US7883705B2 (en) *	2007-02-14	2011-02-08	Kyowa Hakko Kirin Co., Ltd.	Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) *	2010-10-14	2012-04-19	Wisconsin Alumni Research Foundation	Methods for the treatment of x-linked hypophosphatemia and related disorders
US20140294820A1 (en)	2011-06-24	2014-10-02	University Of Miami	Fibroblast growth factor receptor inhibition for the treatment of disease
BR112016028567A2 (pt) *	2014-06-09	2018-01-30	Kyowa Hakko Kirin Co Ltd	método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea
WO2018069232A1 (en)	2016-10-10	2018-04-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of having cardiac hypertrophy
JP7023932B2 (ja)	2017-03-30	2022-02-22	シスメックス株式会社	抗ＡｐｏＡ１抗体
AU2020253833A1 (en) *	2019-03-29	2021-10-28	Atarga, Llc	Anti FGF23 antibody
TW202413406A (zh) *	2022-08-10	2024-04-01	日商協和麒麟股份有限公司	抗fgf23抗體或該抗體片段

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5623587A (en)	1979-08-03	1981-03-05	Mitsuwa Seiki Co Ltd	Vane type compressor
WO1985003934A1 (en)	1984-03-06	1985-09-12	Takeda Chemical Industries, Ltd.	Chemically modified protein and process for its preparation
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61178926U (da)	1985-04-23	1986-11-08
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
FI884924A (fi)	1987-10-28	1989-04-29	Oncogen	Humanimmuglobulin som producerats med hybrid-dna-teknik.
JP2958019B2 (ja)	1988-05-06	1999-10-06	住友製薬株式会社	ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5958879A (en) *	1989-10-12	1999-09-28	Ohio University/Edison Biotechnology Institute	Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6001358A (en)	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
JP4424575B2 (ja)	1998-05-18	2010-03-03	ユニバーシティーカレッジロンドン	新規ポリペプチドホルモン・フォスファトニン
TWI255853B (en)	1998-08-21	2006-06-01	Kirin Brewery	Method for modifying chromosomes
WO2000060085A1 (en)	1999-04-02	2000-10-12	Millennium Pharmaceuticals, Inc.	Fibroblast growth factor-20
US6596849B1 (en) *	1999-05-28	2003-07-22	Academia Sinica	Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
JP2004522402A (ja)	1999-06-02	2004-07-29	ジェネンテック・インコーポレーテッド	同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
AU2055401A (en)	1999-12-01	2001-06-12	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001042451A2 (en)	1999-12-08	2001-06-14	Genset	FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
WO2001049740A1 (en)	2000-01-05	2001-07-12	Zymogenetics, Inc.	Novel fgf homolog zfgf12
JP2003523190A (ja)	2000-02-14	2003-08-05	スミスクライン・ビーチャム・コーポレイション	新規化合物
CA2398603A1 (en)	2000-02-15	2001-08-23	Amgen, Inc.	Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) *	2000-02-15	2006-07-20	Amgen Inc.	Fibroblast Growth Factor-23 molecules and uses thereof
JP2003531583A (ja)	2000-03-08	2003-10-28	カイロンコーポレイション	ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
WO2001066596A2 (en)	2000-03-08	2001-09-13	Chiron Corporation	Human fgf-23 gene and gene expression products
CA2418215A1 (en)	2000-07-19	2002-01-31	Advanced Research & Technology Institute	Novel fibroblast growth factor (fgf23) and methods for use
ES2344679T3 (es)	2000-08-11	2010-09-03	Kyowa Hakko Kirin Co., Ltd.	Polipeptidos que controlan el metabolismo del acido fosforico, el metabolismo del calcio, el metabolismo de la calcificacion y de la vitamina d y moleculas de adn que los codifican.
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
WO2002076467A1 (en)	2001-03-22	2002-10-03	Genzyme Corporation	Compositions and methods to regulate bone and mineral metabolism
AU2002302581A1 (en)	2001-04-26	2002-11-11	Geneprot, Inc.	Human fibroblast growth factor-related compositions
EP2011802A3 (en) *	2001-04-27	2009-04-15	Kyowa Hakko Kirin Co., Ltd.	Anti-CD40 monoclonal antibody
KR101016476B1 (ko) *	2001-12-28	2011-02-24	교와 핫꼬 기린 가부시키가이샤	섬유아세포 증식 인자-23에 대한 항체
US7094551B2 (en) *	2002-09-17	2006-08-22	Zahradnik Richard J	Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
US20070036734A1 (en) *	2003-03-17	2007-02-15	Kirin Beer Kabushiki Kaisha	Therapeutic agent for periodontal disease
BRPI0511782B8 (pt) *	2004-06-03	2021-05-25	Novimmune Sa	anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
PL1773885T3 (pl) *	2004-08-05	2010-09-30	Genentech Inc	Humanizowani antagoniści anty c-met
EP2145954A1 (en) *	2004-09-06	2010-01-20	Kyowa Hakko Kirin Co., Ltd.	Anti-A33 antibody
WO2006078072A1 (ja)	2005-01-21	2006-07-27	Kirin Beer Kabushiki Kaisha	キメラ非ヒト動物およびその使用
US8969532B2 (en)	2006-10-03	2015-03-03	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008092019A1 (en) *	2007-01-25	2008-07-31	Mayo Foundation For Medical Education And Research	Fgf-23 polypeptides
US7883705B2 (en) *	2007-02-14	2011-02-08	Kyowa Hakko Kirin Co., Ltd.	Anti FGF23 antibody and a pharmaceutical composition comprising the same

2008
- 2008-02-13 US US12/030,593 patent/US7883705B2/en active Active
- 2008-02-14 EP EP08711707.3A patent/EP2128253B1/en active Active
- 2008-02-14 DK DK12170984.4T patent/DK2502996T3/da active
- 2008-02-14 PT PT121709844T patent/PT2502996T/pt unknown
- 2008-02-14 PL PL08711707T patent/PL2128253T3/pl unknown
- 2008-02-14 PL PL12170984T patent/PL2502996T3/pl unknown
- 2008-02-14 ES ES17152168T patent/ES2811318T3/es active Active
- 2008-02-14 CN CN201210161119.8A patent/CN102702355B/zh active Active
- 2008-02-14 CN CN2008800048145A patent/CN101652476B/zh active Active
- 2008-02-14 EP EP12170984.4A patent/EP2502996B1/en active Active
- 2008-02-14 PT PT171521685T patent/PT3181691T/pt unknown
- 2008-02-14 LU LU00081C patent/LUC00081I2/en unknown
- 2008-02-14 AU AU2008215346A patent/AU2008215346B2/en active Active
- 2008-02-14 DK DK17152168.5T patent/DK3181691T3/da active
- 2008-02-14 CA CA2677782A patent/CA2677782C/en active Active
- 2008-02-14 WO PCT/JP2008/052918 patent/WO2008099969A1/ja active Application Filing
- 2008-02-14 EP EP17152168.5A patent/EP3181691B1/en active Active
- 2008-02-14 ES ES12170984T patent/ES2625823T3/es active Active
- 2008-02-14 DK DK08711707.3T patent/DK2128253T3/da active
- 2008-02-14 LT LTEP17152168.5T patent/LT3181691T/lt unknown
- 2008-02-14 PL PL17152168T patent/PL3181691T3/pl unknown
- 2008-02-14 SI SI200831797T patent/SI2502996T1/sl unknown
- 2008-02-14 HU HUE17152168A patent/HUE050517T2/hu unknown
- 2008-02-14 LT LTEP12170984.4T patent/LT2502996T/lt unknown
- 2008-02-14 SI SI200832131T patent/SI3181691T1/sl unknown
- 2008-02-14 HU HUE12170984A patent/HUE031728T2/en unknown
- 2008-02-14 ES ES08711707T patent/ES2530670T3/es active Active
- 2008-02-14 PT PT87117073T patent/PT2128253E/pt unknown
- 2008-02-14 KR KR1020097019085A patent/KR101462291B1/ko active Protection Beyond IP Right Term
- 2008-02-14 JP JP2008558165A patent/JP4800396B2/ja active Active
- 2008-02-14 TW TW097105234A patent/TWI422593B/zh active
- 2008-02-14 LU LU00082C patent/LUC00082I2/en unknown
2010
- 2010-06-28 HK HK10106310.8A patent/HK1140228A1/xx unknown
2011
- 2011-02-02 US US13/019,557 patent/US9290569B2/en active Active
2013
- 2013-01-04 HK HK13100123.5A patent/HK1172917A1/xx unknown
2016
- 2016-02-10 US US15/040,103 patent/US10202446B2/en active Active
2017
- 2017-04-04 HR HRP20170548TT patent/HRP20170548T1/hr unknown
- 2017-04-19 CY CY20171100446T patent/CY1118835T1/el unknown
2018
- 2018-07-27 NL NL300945C patent/NL300945I2/en unknown
- 2018-07-27 FR FR18C1032C patent/FR18C1032I2/fr active Active
- 2018-08-01 LT LTPA2018508C patent/LTC2502996I2/lt unknown
- 2018-08-02 HU HUS1800034C patent/HUS1800034I1/hu unknown
- 2018-08-07 CY CY2018021C patent/CY2018021I2/el unknown
- 2018-08-09 NO NO2018025C patent/NO2018025I1/no unknown
- 2018-12-18 US US16/223,930 patent/US20190106485A1/en not_active Abandoned
2020
- 2020-08-03 CY CY20201100713T patent/CY1123240T1/el unknown
- 2020-08-11 HR HRP20201266TT patent/HRP20201266T1/hr unknown

Also Published As

Publication number	Publication date
KR20090114452A (ko)	2009-11-03
ES2811318T3 (es)	2021-03-11
TWI422593B (zh)	2014-01-11
US7883705B2 (en)	2011-02-08
CN102702355A (zh)	2012-10-03
PL2128253T3 (pl)	2015-04-30
EP3181691B1 (en)	2020-07-15
NO2018025I1 (no)	2018-08-09
KR101462291B1 (ko)	2014-11-14
ES2625823T3 (es)	2017-07-20
TW200902549A (en)	2009-01-16
AU2008215346A1 (en)	2008-08-21
CA2677782A1 (en)	2008-08-21
PT2502996T (pt)	2017-05-10
EP2128253A4 (en)	2010-03-10
NL300945I2 (en)	2020-05-13
FR18C1032I2 (fr)	2019-08-09
HK1140228A1 (en)	2010-10-08
WO2008099969A1 (ja)	2008-08-21
CN101652476A (zh)	2010-02-17
HUS1800034I1 (hu)	2018-09-28
PL3181691T3 (pl)	2020-11-02
FR18C1032I1 (da)	2018-08-31
CN102702355B (zh)	2014-09-24
US20190106485A1 (en)	2019-04-11
PL2502996T3 (pl)	2017-07-31
CY2018021I1 (el)	2019-07-10
AU2008215346B2 (en)	2013-01-10
PT2128253E (pt)	2015-02-04
EP2502996A2 (en)	2012-09-26
ES2530670T3 (es)	2015-03-04
CA2677782C (en)	2016-07-26
CY1118835T1 (el)	2018-01-10
LT2502996T (lt)	2017-06-26
DK2128253T3 (da)	2015-01-05
LUC00081I2 (da)	2018-10-01
LTPA2018508I1 (lt)	2018-09-10
HK1172917A1 (en)	2013-05-03
US9290569B2 (en)	2016-03-22
CY1123240T1 (el)	2021-10-29
JPWO2008099969A1 (ja)	2010-05-27
NL300945I1 (en)	2018-08-15
HRP20201266T1 (hr)	2021-02-05
US20090148461A1 (en)	2009-06-11
EP2128253A1 (en)	2009-12-02
EP3181691A1 (en)	2017-06-21
HRP20170548T1 (hr)	2017-08-25
EP2502996B1 (en)	2017-03-29
SI2502996T1 (sl)	2017-08-31
LTC2502996I2 (lt)	2019-05-10
LUC00082I2 (da)	2018-10-01
HUE031728T2 (en)	2017-07-28
US20110182913A1 (en)	2011-07-28
HUE050517T2 (hu)	2020-12-28
EP2502996A3 (en)	2013-04-10
US20160159895A1 (en)	2016-06-09
CY2018021I2 (el)	2019-07-10
LT3181691T (lt)	2020-08-25
CN101652476B (zh)	2012-07-04
SI3181691T1 (sl)	2020-09-30
EP2128253B1 (en)	2014-12-03
PT3181691T (pt)	2020-08-26
JP4800396B2 (ja)	2011-10-26
DK2502996T3 (da)	2017-05-08
US10202446B2 (en)	2019-02-12

Publication	Publication Date	Title
LTC2140867I2 (lt)	2018-11-12	Farmacinė kompozicija
DK2118140T3 (da)	2013-07-01	Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1884242T3 (da)	2013-05-06	Farmaceutisk sammensætning omfattende lurasidon
DK2059535T3 (da)	2014-01-13	Prlr-specifikt antistof og anvendelser deraf
CY2015013I2 (el)	2016-04-13	Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
DK2079485T3 (da)	2012-08-06	Phenylpropionamidforbindelser og anvendelsen deraf
DK2061814T3 (da)	2012-08-27	Antistoffer og immunokonjugater og anvendelse deraf.
DK2209806T3 (da)	2012-09-17	Anti-hepcidin-antistoffer og anvendelser deraf
DK3181691T3 (da)	2020-08-17	Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme
BRPI0717367A2 (pt)	2013-10-22	Di-hidropirazolonas substituídas e sua aplicação.
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
DK1894567T3 (da)	2012-11-19	Ledsagende farmaceutiske midler og anvendelse deraf
DK1957073T3 (da)	2014-05-12	Lægemiddel
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
BRPI0714539A2 (pt)	2014-02-25	"formas farmacêuticas"
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
DK2170827T3 (da)	2013-11-18	Indolin-2-oner og aza-indolin-2-oner
DK2001556T3 (da)	2014-11-10	Thioninium-forbindelser og anvendelse deraf
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
DK2207773T3 (da)	2012-09-10	Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
ATE493119T1 (de)	2011-01-15	Pharmazeutische zusammensetzung
DE602008005137D1 (de)	2011-04-07	Chinolonverbindung und pharmazeutische zusammensetzung
DK2029561T3 (da)	2014-11-10	Tricyclisk forbindelse og farmaceutisk anvendelse deraf
DK2231603T3 (da)	2013-06-03	Substituerede 3-hydroxypyridiner og farmaceutiske sammensætninger deraf